Japan Tissue Engineering Co., Ltd. (7774) AI Stock Analysis

• Market Cap: ¥23.03B
• Dividend Yield: N/A
• Average Volume (3M): 76.19K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.03
• Revenue Growth: -2.34%
• EPS Growth: -278.32%
• Country: JP
• Employees: 211
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): 2.33
• Shares Outstanding: 40,610,200
• 10 Day Avg. Volume: 57,310
• 30 Day Avg. Volume: 76,193
• PEG Ratio: -0.62
• Price to Book (P/B): 3.56
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -26.49
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 58 Neutral
• Price Target: ―

Japan Tissue Engineering Co., Ltd. scores moderately due to a strong balance sheet and technical momentum. However, profitability and cash flow concerns, alongside a negative P/E ratio, weigh on the overall assessment. The company's financial stability provides a foundation, but the lack of earnings growth and cash flow issues are key risks.

Japan Tissue Engineering Co., Ltd. Business Overview & Revenue Model

Company Description

Japan Tissue Engineering Co., Ltd. engages in the regenerative medicine business in Japan. The company operates through Regenerative Medicine Product, Regenerative Medicine Outsourcing, and Research and Development Support segments. It offers autologous cultured epidermis, cartilage, corneal epithelium, and oral mucosal epithelium to medical institutions for the purpose of medical treatment. The company also provides tissue-engineered medical products. In addition, it researches and develops human 3-dimensional cultured tissue models for use in the development of cosmetics and drugs for external use, as well as in research that employs skin and cornea tissues. Further, the company offers regenerative medicine contract development and manufacturing services. The company was founded in 1999 and is headquartered in Gamagori, Japan. Japan Tissue Engineering Co., Ltd. is a subsidiary of Teijin Limited.

How the Company Makes Money

J-TEC generates revenue through the sale of its tissue-engineered products, which are used in medical treatments and procedures. The company's primary revenue streams come from the commercial sales of its cultured tissue products to hospitals and medical institutions. Additionally, J-TEC is involved in collaborative research and development projects with academic institutions and other corporations, which may provide additional funding and revenue opportunities. The company also invests in intellectual property development and may earn income through licensing agreements or partnerships with other entities in the regenerative medicine space.

Japan Tissue Engineering Co., Ltd. Financial Statement Overview

Summary

Japan Tissue Engineering Co., Ltd. presents a mixed financial picture. While the balance sheet is strong with no debt and high equity, profitability challenges are evident with negative net income and EBIT margins. The cash flow statement highlights potential cash management issues, transitioning from positive to zero free cash flow.

Income Statement

The company has shown erratic revenue patterns with recent declines in revenue from the annual to TTM period. Gross profit margins remain relatively high, but negative net income and EBIT margins indicate ongoing profitability challenges. Despite previous growth, the most recent TTM figures show significant financial distress.

Balance Sheet

The balance sheet reflects strong equity with no debt, which indicates financial stability and low leverage. The high equity ratio suggests the company is well-capitalized. However, the consistent negative net income impacts return on equity, which remains negative.

Cash Flow

The cash flow statement shows a lack of positive free cash flow and operating cash flow, which could concern stakeholders. The transition from positive free cash flow in the previous year to zero in the TTM period underlines potential cash management issues.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	2.44B	2.46B	2.51B	2.03B	2.10B	2.26B
Gross Profit	1.49B	1.47B	1.69B	1.14B	1.26B	1.16B
EBITDA	12.67M	-76.02M	278.56M	-597.00M	-374.00M	-359.89M
Net Income	-153.61M	-255.30M	143.17M	-729.32M	-497.89M	-466.62M
Balance Sheet
Total Assets	6.45B	6.51B	6.99B	6.88B	7.60B	8.12B
Cash, Cash Equivalents and Short-Term Investments	4.07B	3.89B	4.27B	4.13B	4.93B	5.28B
Total Debt	0.00	0.00	0.00	133.00K	936.00K	1.74M
Total Liabilities	717.83M	687.95M	908.43M	946.15M	931.66M	954.78M
Stockholders Equity	5.73B	5.83B	6.08B	5.94B	6.67B	7.16B
Cash Flow
Free Cash Flow	0.00	-224.48M	938.00K	-798.60M	-342.48M	-473.98M
Operating Cash Flow	0.00	-148.37M	274.14M	-622.60M	-225.25M	-399.59M
Investing Cash Flow	0.00	-232.53M	-242.23M	1.12B	-116.48M	125.89M
Financing Cash Flow	0.00	-3.00K	-134.00K	-803.00K	-823.00K	-1.30M

Japan Tissue Engineering Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 567.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:7774, the sentiment is Neutral. The current price of 567 is below the 20-day moving average (MA) of 597.70, below the 50-day MA of 601.32, and above the 200-day MA of 514.99, indicating a neutral trend. The MACD of -4.96 indicates Positive momentum. The RSI at 42.06 is Neutral, neither overbought nor oversold. The STOCH value of 8.19 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:7774.

Japan Tissue Engineering Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7096	61 Neutral	¥9.68B	25.09		―	7.98%	24.12%
7774	58 Neutral	¥23.03B	―		―	-2.34%	-278.32%
Sector *	52 Neutral	$7.50B	0.31	-61.87%	2.27%	17.10%	1.59%
4978	49 Neutral	¥17.82B	179.65		―	8.46%	49.97%
4599	47 Neutral	¥19.01B	―		―	-100.00%	-1079.89%
7776	45 Neutral	¥16.22B	―		―	-4.04%	-0.88%
4593	37 Underperform	¥44.28B	―		―	374.19%	35.53%

Japan Tissue Engineering Co., Ltd. Corporate Events

Japan Tissue Engineering Co., Ltd. Reports Third Quarter Financial Results and Adjusted Forecast

Japan Tissue Engineering Co., Ltd. reported a decrease in net sales and net income for the third quarter of FY2024 compared to the previous year, reflecting ongoing financial challenges. The company has revised its forecasts for FY2024, indicating a cautious outlook amid a competitive market environment, which could have implications for its stakeholders and market position.